Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer.
Breast cancer
Genomic risk
HER2-Low
Oncotype DX RS
Prognosis
Journal
Breast (Edinburgh, Scotland)
ISSN: 1532-3080
Titre abrégé: Breast
Pays: Netherlands
ID NLM: 9213011
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
19
06
2021
revised:
06
08
2021
accepted:
16
08
2021
pubmed:
5
9
2021
medline:
28
12
2021
entrez:
4
9
2021
Statut:
ppublish
Résumé
Recent data suggest that human epidermal growth factor receptor 2 (HER2)-low breast cancer may represent a distinct entity. We aimed to compare disease characteristics and outcomes between HER2-low and HER2-0 in estrogen receptor (ER) positive, early-stage breast cancer. A single center retrospective study comprising all women with ER positive, HER2 negative early breast cancer, for whom an Oncotype DX test was performed between 2005 and 2012. Women were grouped to HER2-low (immunohistochemistry +1 or +2 and in situ hybridization not amplified) or HER2-0. Clinico-pathological features and Oncotype recurrence score (RS) were collected. Data on overall-survival (OS), disease-free survival (DFS) and distant disease-free survival (DDFS) were evaluated according to HER2 expression status. 608 women were included, of which 304 women had HER2-0 and 304 had HER2-low disease. Lobular subtype was significantly more common in HER-0 compared to HER2-low disease (17% vs. 8%, p = 0.005). The prevalence of other clinic-pathological characteristics and long-term prognosis were comparable between both groups. For women with high genomic risk (RS > 25), HER2-low expression was associated with significantly favorable OS (HR = 0.31, 95% CI 0.11-0.78, p = 0.01), DFS (HR = 0.40, 95% CI 0.20-0.82, p = 0.01) and DDFS (HR = 0.26, 95% CI 0.11-0.63, P = 0.002) compared to women with HER2-0. For women with low genomic risk (RS ≤ 25), long-term prognosis was unrelated to HER2 expression. The prognostic impact of HER2-low expression in early-stage luminal disease varies across the genomic risk, with significant favorable outcomes of HER2-low expression compared to HER2-0 in women with high genomic risk.
Sections du résumé
BACKGROUND
BACKGROUND
Recent data suggest that human epidermal growth factor receptor 2 (HER2)-low breast cancer may represent a distinct entity. We aimed to compare disease characteristics and outcomes between HER2-low and HER2-0 in estrogen receptor (ER) positive, early-stage breast cancer.
METHODS
METHODS
A single center retrospective study comprising all women with ER positive, HER2 negative early breast cancer, for whom an Oncotype DX test was performed between 2005 and 2012. Women were grouped to HER2-low (immunohistochemistry +1 or +2 and in situ hybridization not amplified) or HER2-0. Clinico-pathological features and Oncotype recurrence score (RS) were collected. Data on overall-survival (OS), disease-free survival (DFS) and distant disease-free survival (DDFS) were evaluated according to HER2 expression status.
RESULTS
RESULTS
608 women were included, of which 304 women had HER2-0 and 304 had HER2-low disease. Lobular subtype was significantly more common in HER-0 compared to HER2-low disease (17% vs. 8%, p = 0.005). The prevalence of other clinic-pathological characteristics and long-term prognosis were comparable between both groups. For women with high genomic risk (RS > 25), HER2-low expression was associated with significantly favorable OS (HR = 0.31, 95% CI 0.11-0.78, p = 0.01), DFS (HR = 0.40, 95% CI 0.20-0.82, p = 0.01) and DDFS (HR = 0.26, 95% CI 0.11-0.63, P = 0.002) compared to women with HER2-0. For women with low genomic risk (RS ≤ 25), long-term prognosis was unrelated to HER2 expression.
CONCLUSION
CONCLUSIONS
The prognostic impact of HER2-low expression in early-stage luminal disease varies across the genomic risk, with significant favorable outcomes of HER2-low expression compared to HER2-0 in women with high genomic risk.
Identifiants
pubmed: 34481367
pii: S0960-9776(21)00436-7
doi: 10.1016/j.breast.2021.08.016
pmc: PMC8414540
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Hormones
0
Receptors, Estrogen
0
Receptors, Progesterone
0
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
62-69Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest All other authors have no conflicts of interest.
Références
N Engl J Med. 2004 Dec 30;351(27):2817-26
pubmed: 15591335
J Natl Cancer Inst. 2018 Jan 1;110(1):
pubmed: 28922787
Lancet Oncol. 2021 Aug;22(8):1151-1161
pubmed: 34252375
Lancet. 2015 Oct 3;386(10001):1341-1352
pubmed: 26211827
Ann Oncol. 2017 Aug 1;28(8):1700-1712
pubmed: 28838210
Semin Cancer Biol. 2021 Jul;72:123-135
pubmed: 32112814
N Engl J Med. 2019 Sep 26;381(13):1284-1286
pubmed: 31502769
J Clin Oncol. 2016 Jul 20;34(21):2452-9
pubmed: 27217455
N Engl J Med. 2019 Jun 20;380(25):2395-2405
pubmed: 31157962
J Natl Cancer Inst. 2014 Apr 28;106(5):
pubmed: 24777111
N Engl J Med. 2005 Oct 20;353(16):1673-84
pubmed: 16236738
Am J Pathol. 2013 Nov;183(5):1446-1460
pubmed: 24035511
Breast Cancer Res. 2004;6(3):R149-56
pubmed: 15084238
J Clin Oncol. 2006 Mar 1;24(7):1037-44
pubmed: 16505422
Breast. 2016 Feb;25:57-61
pubmed: 26612082
Lancet Oncol. 2019 Aug;20(8):1124-1135
pubmed: 31257177
J Clin Oncol. 2018 Jul 10;36(20):2105-2122
pubmed: 29846122
J Clin Oncol. 2010 Sep 20;28(27):4120-8
pubmed: 20585090
Ann Oncol. 2019 Oct 1;30(10):1541-1557
pubmed: 31373601
Cancer Res. 2003 Apr 1;63(7):1445-8
pubmed: 12670887
N Engl J Med. 2018 Jul 12;379(2):111-121
pubmed: 29860917
J Clin Oncol. 2020 Jun 10;38(17):1951-1962
pubmed: 32330069
Semin Diagn Pathol. 2010 Feb;27(1):49-61
pubmed: 20306830
Ann Oncol. 2008 Oct;19(10):1706-12
pubmed: 18544559
Cancers (Basel). 2021 Jun 05;13(11):
pubmed: 34198891
J Clin Oncol. 2020 Feb 10;38(5):444-453
pubmed: 31821109
J Clin Oncol. 2020 Jun 10;38(17):1887-1896
pubmed: 32058843
J Clin Oncol. 2021 Feb 20;39(6):557-564
pubmed: 33306425
NPJ Breast Cancer. 2021 Jan 4;7(1):1
pubmed: 33397968
Oncologist. 2012;17(11):1418-25
pubmed: 22951668
Br J Cancer. 1957 Sep;11(3):359-77
pubmed: 13499785
Curr Opin Oncol. 2020 Sep;32(5):494-502
pubmed: 32657795
Cancer Prev Res (Phila). 2014 Apr;7(4):378-87
pubmed: 24441675
Ann Oncol. 2019 Aug 1;30(8):1194-1220
pubmed: 31161190
Endocr Relat Cancer. 2015 Oct;22(5):725-33
pubmed: 26187126
Lancet Oncol. 2010 Jan;11(1):55-65
pubmed: 20005174
Am J Surg Pathol. 2009 May;33(5):759-67
pubmed: 19252432